Testimonials

Background stories of how others approached and experienced their European Horizon funding trajectory.

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Published on | 1 week ago

Programmes Health

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.

Read the full article for details 
Other available testimonials

Testimonial

image of Lorcenis - Long Lasting Reinforced Concrete for Energy Infrastructures under Severe Operating Conditions

Lorcenis - Long Lasting Reinforced Concrete for Energy Infrastructures under Severe Operating Conditions

ChemStream is an innovative chemical R&D company, specialized in translating material problems in sustainable formulations with focus on nano-dispersions, functional coatings and inkjet inks. Within LORCENIS they will develop super absorbing polymers (SAPs) to be mixed within the concrete matrices for improving the active internal curing, self-healing and self-sealing properties of the concrete. Grindig SAPs.

ChemStream bvba and Ghent University are involved in Horizon 2020-project for developing long lasting reinforced concrete for energy infrastructures.